Fekade B Sime retweeted
Observed 365-day cumulative incidences were 19.3% for any amputation and 6.4% for major amputation #idxposts
🆕💥🟢Predicting 365-Day Lower-Limb Amputation at Discharge After Diabetes-Related Foot Ulcer Hospitalization: Development and Temporal Validation
Observed 365-day cumulative incidences were 19.3% for any amputation and 6.4% for major amputation #idxposts academic.oup.com/ofid/articl…
Fekade B Sime retweeted
Stability of tigecycline in elastomeric devices for OPAT - Tigecycline meets the 🇬🇧 YCD criteria of ≤5% degradation limit. Fantastic collaboration with 🌍 colleagues @jasonroberts_pk @b_fekade @raseaton66 @BSACandJAC academic.oup.com/jacamr/arti…
Fekade B Sime retweeted
Our article: doi.org/10.1093/jac/dkae058… has been selected for inclusion in the Best of Journal of Antimicrobial Chemotherapy 2024.
@b_fekade @jasonroberts_pk @CRE_RESPOND #UQCCR @UQMedicine @UQ_News
academic.oup.com/jac/pages/b…
Fekade B Sime retweeted
‘By standardising stability testing guidelines, we can broaden treatment options for patients with serious infections, improve clinical outcomes, advance antimicrobial stewardship, and reduce healthcare costs.’ bsac.org.uk/call-for-global-… @b_fekade @jasonroberts_pk @CRE_RESPOND @UQMedicine @UQ_News @raseaton66 @MGilchrist123
Fekade B Sime retweeted
Is it time for global harmonization of opat drug stability testing frameworks? Great to collaborate with @jasonroberts_pk @b_fekade @CRE_RESPOND @raseaton66 @BSACandJAC & many more - onto the next step! academic.oup.com/jacamr/arti…
Fekade B Sime retweeted
🆕️🔥State of the art review article #JAC 🌟s @jasonroberts_pk @b_fekade @MGilchrist123
Current Practices and challenges of outpatient parenteral antimicrobial therapy #OPAT #IDXposts #bookmark
Great tables🎯
academic.oup.com/jac/article…
Fekade B Sime retweeted
In OPAT settings, continuous 12 h CZA infusion may be possible in territories where degradation of ≤10% is deemed acceptable
But avoid prolonged fridge storage (>72h) to keep overall sequential degradation to <10%:
doi.org/10.1093/jacamr/dlae0…
@b_fekade @jasonroberts_pk #JACAMRNews
Fekade B Sime retweeted
Great to see this - Evaluation of stability of ceftazidime/avibactam in elastomeric infusion devices used for OPAT. 🇬🇧 & 🇦🇺 partnership in this space continues @b_fekade @jasonroberts_pk @raseaton66 @jamiesonce & more academic.oup.com/jacamr/arti…
Fekade B Sime retweeted
You're invited to an exciting 3-day workshop on Antimicrobial Optimisation: Population pharmacokinetic modeling and dosing software.
30 places available
Reg: lnkd.in/dPb-X6fP
@jasonroberts_pk @DocJamesPollard @legg_wamy @davidantibiotic @IATDMCT @NCICancer @PattyMitre_
Fekade B Sime retweeted
You're invited to an exciting 3-day workshop on Antimicrobial Optimisation: Population pharmacokinetic modeling and dosing software. 30 places available Reg: lnkd.in/dPb-X6fP
@jasonroberts_pk
@DocJamesPollard
@legg_wamy
@SuzieParker_CMG
@IATDMCT
@NCICancer
@PattyMitre_
Fekade B Sime retweeted
Join ISAC's Anti-Infective Pharmacology Working Group free of cost
forms.gle/wFC6G7ZJsYJujgu46
Supported by @CRE_REDUCE , we published 33 papers on PK/PD of antimicrobials since 2019. Exting time as we transition to #CRE_RESPOND @jasonroberts_pk #Steategicretreat
Fekade B Sime retweeted
Live Roundtable Discussion on
Clinical Trials Targeting Antimicrobial
Resistance with @davidantibiotic ,DR. Mo Yin and @davidlye70
Fekade B Sime retweeted
Lots happening at CRE REDUCE in the next few months!
Check out our upcoming education events cre-reduce.centre.uq.edu.au/…!
@jasonroberts_pk
Fekade B Sime retweeted
It’s very nice to “see” everyone at #ECCMID2021. I’m struck that despite the last 18/12, so little has changed in the #AMR world. We are good at describing the problem but seem to be less interested in radical thinking that is required to minimise the impact of AMR. 1/6
Fekade B Sime retweeted
Hello OPAT / HITH/ IV@home communities - antibiotic stability question for you! What buffers are used in continuous abx infusions in your service. Poll below or feel free to reply with more information! @BSACandJAC @jamiesonce @jasonroberts_pk @b_fekade @UKCPAPIN
48%Citrate
7%Phosphate
7%Citrate-phosphate
38%None
29 votes • Final results Fekade B Sime retweeted
It would make sense that high aminoglycoside concentrations achieved in the lungs after nebulisation would optimise bacterial killing for patients with pneumonia. But why has it failed in clinical trials? One potential factor is the epithelial lining fluid link.springer.com/article/10…
Fekade B Sime retweeted
Checkout my point of view on #COVID19Vaccine @AustralianCRS @UQHealth @UQPharmacy Thank you @WolframJoy for creating this beautiful graphic and @CRS_FG_NANO for this opportunity – at Brisbane, Queensland
